Hypertension and proteinuria: a class-effect of antiangiogenic therapies

V Launay-Vacher, G Deray - Anti-cancer drugs, 2009 - journals.lww.com
Antiangiogenic therapy has now become a cornerstone in the treatment of several solid
tumor cancers. Those drugs present with a renal toxicity profile manifesting as proteinuria …
被引用次数：127 相关文章

[引用][C] Hypertension and proteinuria: a class-effect of antiangiogenic therapies

V Launay-Vacher, G Deray - Anti-Cancer Drugs, 2009 - cir.nii.ac.jp
Hypertension and proteinuria: a class-effect of antiangiogenic therapies | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

Hypertension and proteinuria: a class-effect of antiangiogenic therapies

V Launay-Vacher, G Deray - Anti-cancer drugs, 2009 - pubmed.ncbi.nlm.nih.gov
Antiangiogenic therapy has now become a cornerstone in the treatment of several solid
tumor cancers. Those drugs present with a renal toxicity profile manifesting as proteinuria …

Hypertension and proteinuria: a class-effect of antiangiogenic therapies.

V Launay-Vacher, G Deray - Anti-cancer Drugs, 2009 - europepmc.org
Antiangiogenic therapy has now become a cornerstone in the treatment of several solid
tumor cancers. Those drugs present with a renal toxicity profile manifesting as proteinuria …
[PDF] academia.edu

[PDF][PDF] Hypertension and proteinuria: a class-effect of antiangiogenic therapies

V Launay-Vacher, G Deray - Anti-Cancer Drugs, 2009 - academia.edu
Antiangiogenic therapy has now become a cornerstone in the treatment of several solid
tumor cancers. Those drugs present with a renal toxicity profile manifesting as proteinuria …